Hepatocellular carcinoma
Conditions
Interventions
1:Iodine-125 seeds strand and stent were placed in the obstucted MPV combined with TACE
2:Stent was placed in the obstructed MPV combined with TACE
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. diagnosis of HCC confirmed by histology, cytology, or persistently elevated serum alpha-fetoprotein (AFP) (> 400ng/ml) with typical imaging findings; 2. the unsuitability of HCC for resection, liver transplantation or percutaneous ablation according to Barcelona Clinical Liver Cancer (BCLC) staging classification; 3. MPV tumor thrombus was diagnosed by the imaging criteria: filling defect with enhancement was founded in MPV on the arterial phase of enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scan before therapy; 4. at least, the second-order branch of the intrahepatic portal vein being patent in one lobe; 5. no prior therapy for MPV tumor thrombus; 6. Child-Pugh classification grade A or B; 7. Eastern Cooperative Oncology Group (ECOG) performance status < 2.
Exclusion criteria
Exclusion criteria: 1. refused to endovascular brachytherapy or cannot follow the study protocol; 2. intrahepatic portal vein completely occluded by HCC; 3. superior mesenteric vein or splenic vein or both involved by tumor thrombus; 4. contraindications for TACE, including HCC burden> 50% of total liver volume, high flow intrahepatic arteriovenous shunt, total bilirubin >51umol/L, albumin5 times upper limit of normal range, creatinine >115umol/L, leukocyte count 6s above control.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| stent patency; | — |
Countries
China
Contacts
Public ContactZhiping Yan
Outcome results
None listed